EXTENDING K-DUR’S REACH? FTC FILES AMICUS BRIEF ARGUING THAT PHARMACEUTICAL PATENT LITIGATION SETTLEMENTS CONTAINING “NO-AG” PROVISIONS ARE ANTICOMPETITIVE* The Federal Trade Commission (FTC) filed an amicus brief on October 9 in U.S. District Court (D.N.J.). In it, the FTC spells out its arguments why, as part of a pharmaceutical patent litigation settlement agreement, a branded company’s promise not to launch an authorized generic (AG) version of its product during the generic firm’s 180-day marketing exclusivity period is a "pay-for-delay" agreement in violation of the antitrust laws, if the agreement also contains the generic’s promise to defer its entry. The FTC argues that
Share on
|
|
The US FTC files an amicus brief arguing that pharmaceutical patent litigation settlements with ’no authorized generic’ provisions are anticompetitive (GSK / Louisiana Wholesale Drug)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
